No products in the cart.
Pre-made Socazolimab benchmark antibody ( Whole mAb, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-695
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Socazolimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Socazolimab (also known as STI A1014, STI 1014) is?a fully human monoclonal antibody targeting the programmed death ligand 1 (PD-L1), being developed by Lees Pharmaceutical
| Products Name (INN Index) | Pre-Made Socazolimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody |
|---|---|
| INN Name | Socazolimab |
| Target | CD274 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | Sorrento Therapeutics,China Oncology Focus Ltd,Lee's Pharmaceutical |
| Conditions Approved | NA |
| Conditions Active | Small cell lung cancer,Oesophageal cancer,Osteosarcoma,Urogenital cancer,Cervical cancer,Malignant melanoma |
| Conditions Discontinued | Cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD274 |
| Package |
Previous slide
Next slide
